CoRegen Secures $93 Million to Advance Novel Treg Cell Therapies into Clinic

HOUSTON, July 9, 2025 – CoRegen, Inc., a biopharmaceutical company dedicated to developing innovative treatments for aggressive cancers, today announced the successful close of a $93.39 million financing round. This substantial investment will accelerate the company’s chemistry, manufacturing, and controls (CMC) development and fund the initiation of a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (SRC3-KO Treg) cells program. This program targets various solid tumor types, with the trial expected to commence in the first half of 2026. Proceeds will also support the expansion of CoRegen’s leadership team to drive execution and company growth.

This financing was secured through a private placement with a select group of investors, building on CoRegen’s earlier $28 million raise in early 2024. That prior funding facilitated the acquisition of an exclusive license from Baylor College of Medicine for CoRegen’s innovative gene regulatory platform.

“We are delighted to have the support of our investors during this pivotal time of growth for the company,” said Suneet Varma, CoRegen’s newly appointed Chairman. “This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief that our master gene regulatory platform offers a potentially paradigm-shifting solution for patients battling some of the most difficult-to-treat solid-tumor cancers, including triple-negative breast cancer and glioblastoma. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer.”

CoRegen’s pioneering platform is founded on the groundbreaking work on steroid receptor coactivators (SRCs) by Bert O’Malley, M.D., Chancellor at the Baylor College of Medicine and widely recognized as the “Father of Molecular Endocrinology.” Given that SRC-3 is overexpressed in most human cancers and that Treg cells’ cancer protection activity is dependent on SRC-3, CoRegen has meticulously engineered cells where SRC-3 is knocked out using its proprietary platform. This approach enables the targeting of a broad network of immune checkpoint genes, aiming for a superior anti-tumor effect. These SRC genes, discovered 30 years ago by Dr. O’Malley, possess the remarkable ability to regulate a wide number of genes, serving as an ideal master on-off switch for either stimulating or suppressing gene expression.